Omid Akbari, PhD

Professor of Immunology and Immune Therapeutics and Medicine

Image of Omid Akbari, PhD
Is this your profile? Click to edit

Overview

We are cellular and molecular immunologists dedicated to advancing the understanding of the immune system. Our laboratory focuses on characterizing both innate and acquired immune responses, uncovering the mechanisms that regulate them, and investigating how they contribute to inflammatory diseases. We manipulate cell signaling pathways, costimulatory molecules, and cellular energy sources to modulate immune function and improve human health. Ultimately, our goal is to identify precise strategies to harness and control these responses for therapeutic benefit.

Awards

  • USC: Omid Akbari, 2025
     – 2030
  • Stanford University: American Lung Association award, 2001
     – 2003
  • Stanford University and Harvard Medical School: American Lung Association Grant Award, 2003
     – 2005
  • Stanford University: Pharmacia Research Foundation Award for the best research in the field of Immunology, Stockholm, 2003
  • Stanford University: Pharmacia Research Foundation Award for the best research in the field of Immunology, Amsterdam, 2004
  • Harvard Medical School: Pharmacia Research Foundation Award for the best research in the field of Immunology, Munich, 2005
  • Harvard Medical School: Henning Lowenstein Award for the best research in the field of Allergy and Immunology, Munich, 2005
  • Harvard Medical School: Eleanor & Miles Shore Career Development Award, 2007
     – 2008
  • Harvard Medical School: Children’s Hospital of Boston Career Development Award, 2007
     – 2008
  • University of Southern California: Ideas Empowered Award, 2012
     – 2013
  • University of Southern California: National Academy of Inventors Award, 2017
     – 2018
  • University of Southern California: Keck School of Medicine Dean’s award for scholarship, 2023

Research Funding

  • Mechanisms of Perinatal Nicotine Vaping-Induced Pulmonary ILC2 Dysregulation and Allergic Asthma Development
    NIH · R01HL183124 · Sep 1, 2026 – May 31, 2030 · Role: Co-Principal Investigator
  • Study the role of ICOS on murine and human ILC2s
    NIH · R01AI181866 · Jun 11, 2025 – May 31, 2030 · Role: Principal Investigator
  • Transcriptional and metabolomic regulation of IL-10 in pulmonary ILC2s
    NIH · R01AI169687 · Sep 20, 2022 – Jul 31, 2027 · Role: Principal Investigator
  • Role of TNF receptor 2 on Pulmonary Group 2 Innate Lymphoid Cells
    NIH · R01HL159804 · Dec 15, 2021 – Nov 30, 2025 · Role: Principal Investigator
  • Study the link of autophagy dysfunction to allergic and neutrophilic asthma onset
    NIH · R01HL151493 · Jul 1, 2020 – Jun 30, 2025 · Role: Principal Investigator
  • Induction of cells and pathways that promote respiratory tolerance in allergic asthma
    NIH · R01HL144790 · Sep 1, 2019 – Aug 31, 2023 · Role: Principal Investigator
  • Maternal effect on offspring immunity against hepatitis B virus
    NIH · R01AI145813 · Jul 3, 2019 – Jun 30, 2025 · Role: Co-Principal Investigator
  • Role of Microbiome Sodium Butyrate in regulation of ILC2 dependent airway hyperreactivity
    NIH · R21AI132084 · May 18, 2017 – Apr 30, 2020 · Role: Principal Investigator
  • The function of CRAC channels in airway inflammation
    NIH · R21AI109059 · Jan 1, 2016 – Dec 31, 2017 · Role: Co-Principal Investigator
  • Genetic and Environmental Determinants of Asthma Endophenotypes
    NIH · R01ES025786 · Aug 1, 2015 – Apr 30, 2021 · Role: Co-Principal Investigator
  • Air pollution, immune modulation of adipose tissue and type-2 diabetes risk factors
    NIH · R21ES024707 · Jul 10, 2014 – Jun 30, 2018 · Role: Co-Principal Investigator
  • INTEGRATIVE GENETIC APPROACHES TO GENE-AIR POLLUTION INTERACTIONS IN ASTHMA
    NIH · R01ES021801 · Aug 1, 2012 – Oct 31, 2019 · Role: Co-Principal Investigator
  • Role of NKT cells in airway hyperreactivity &tolerance
    NIH · R01AI066020 · Sep 20, 2007 – Aug 31, 2014 · Role: Principal Investigator

Publications

  • ICOS regulates IL-10 production in group 2 innate lymphoid cells via cholesterol and cortisol biosynthesis. J Clin Invest. 2025 09 16; 135(18).. View in PubMed
  • Multiple chemical sensitivity (MCS) validity, prevalence, tools and interventions: systematic review protocol. BMJ Open. 2025 May 08; 15(5):e088136.. View in PubMed
  • BTLA agonist attenuates Th17-driven inflammation in a mouse model of steroid-resistant asthma. Front Immunol. 2025; 16:1552394.. View in PubMed
  • Integrated workflow for analysis of immune enriched spatial proteomic data with IMmuneCite. Sci Rep. 2025 Mar 19; 15(1):9394.. View in PubMed
  • FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions. J Clin Invest. 2025 Jan 02; 135(4).. View in PubMed
  • Sensory neurons regulate stimulus-dependent humoral immunity in mouse models of bacterial infection and asthma. Nat Commun. 2024 10 16; 15(1):8914.. View in PubMed
  • SIRPα engagement regulates ILC2 effector function and alleviates airway hyperreactivity via modulating energy metabolism. Cell Mol Immunol. 2024 10; 21(10):1158-1174.. View in PubMed
  • Sensory neurons regulate stimulus-dependent humoral immunity. bioRxiv. 2024 Aug 13.. View in PubMed
  • IMmuneCite: an integrated workflow for analysis of immune enriched spatial proteomic data. Res Sq. 2024 Jul 09.. View in PubMed
  • CB2 stimulation of adipose resident ILC2s orchestrates immune balance and ameliorates type 2 diabetes mellitus. Cell Rep. 2024 07 23; 43(7):114434.. View in PubMed